NASDAQ$ASTH
Astrana Health Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Astrana Health Inc reported Q2 2025 results with revenue growth driven by acquisitions and capitation expansion.
Astrana Health Inc achieved total revenue of $654.8 million for the three months ended June 30, 2025, up 35% year-over-year, primarily from capitation revenue increases due to recent acquisitions and enrollment growth in its Restricted Knox-Keene plans. Net income attributable to the company was $9.4 million with basic and diluted EPS of $0.19. Operating income declined to $20.3 million amid higher medical costs and general and administrative expenses supporting growth.
- Total revenue reached $654.8 million, a 35% increase year-over-year, led by $171.5 million growth in capitation revenue.
- Net income attributable to Astrana Health, Inc. was $9.4 million ($0.19 EPS), down from $19.2 million in Q2 2024.
- Adjusted EBITDA was $48.1 million, essentially flat year-over-year despite higher utilization and transaction costs.
- Cash and cash equivalents stood at $339.7 million with total assets of $1.44 billion at quarter end.
Headline financials
Revenue & EPS history
Astrana Health · Revenue · Quarterly
$655M
Revenue by segment
Astrana Health · $631M total across 1 segment · Q2 2025
- Care Partners$631M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.7%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.1%
Avg return
30 days after
40%
23 / 57 earnings
Positive
+83.3%
Q3 2011
Best reaction
-40.5%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | +29.4% | +22.5% | +20.6% | |
| Q3 2025 | -23.4% | -29.4% | -33.8% | |
| Q1 2025 | -11.1% | -20.8% | -24.5% | |
| Q4 2024 | -26.8% | +5.0% | +16.1% | |
| Q3 2024 | -21.1% | -27.9% | -30.4% | |
| Q2 2024 | -1.4% | -1.8% | +0.1% | |
| Q1 2024 | -0.7% | +1.5% | +8.0% | |
| Q4 2023 | +2.3% | +1.8% | -1.9% | |
| Q3 2023 | +9.3% | +2.9% | +13.4% | |
| Q2 2023 | +4.2% | +3.5% | -17.4% | |
| Q1 2023 | +5.4% | +7.0% | -0.8% | |
| Q4 2022 | +6.9% | +5.2% | +15.2% | |
| Q3 2022 | +8.4% | +8.9% | -14.5% | |
| Q2 2022 | -4.3% | -11.0% | -29.3% | |
| Q1 2022 | -0.5% | -5.4% | -26.4% | |
| Q4 2021 | -2.0% | -11.0% | -7.0% | |
| Q3 2021 | +14.7% | +30.5% | +0.8% | |
| Q2 2021 | -11.8% | -10.7% | -12.9% | |
| Q1 2021 | +4.5% | +4.7% | +10.9% | |
| Q4 2020 | +9.1% | +8.8% | +8.3% | |
| Q3 2020 | -1.2% | -1.6% | +0.5% | |
| Q2 2020 | +1.8% | +2.4% | +7.9% | |
| Q1 2020 | -10.4% | -11.6% | +13.1% | |
| Q4 2019 | -12.9% | -24.0% | +7.0% | |
| Q3 2019 | -2.9% | -0.9% | +25.0% | |
| Q2 2019 | -5.0% | +4.8% | +31.1% | |
| Q1 2019 | -1.2% | -4.3% | -29.7% | |
| Q4 2018 | -6.4% | -8.3% | -6.9% | |
| Q3 2018 | +26.3% | +4.0% | -4.6% | |
| Q2 2018 | -13.7% | -23.3% | -32.2% | |
| Q4 2017 | +10.8% | -6.3% | +2.1% | |
| Q1 2018 | +10.8% | -6.3% | +2.1% | |
| Q3 2017 | +3.9% | +3.9% | +140.0% | |
| Q2 2017 | +0.0% | +0.0% | -10.5% | |
| Q1 2017 | +0.0% | +6.7% | +36.7% | |
| Q1 2016 | +4.0% | +4.0% | +0.0% | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | -12.9% | — | — | |
| Q1 2015 | -6.5% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q2 2014 | +15.6% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | +1.6% | — | — | |
| Q2 2013 | +13.5% | — | — | |
| Q1 2013 | -13.3% | — | — | |
| Q4 2012 | -2.2% | — | — | |
| Q3 2012 | -9.1% | — | — | |
| Q2 2012 | -40.5% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | +83.3% | — | — | |
| Q2 2011 | +0.5% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | -3.9% | — | — | |
| Q3 2010 | +19.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | -2.1% | — | — | |
| Q4 2009 | +9.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro